1. Home
  2. PHIO vs FLYX.WS Comparison

PHIO vs FLYX.WS Comparison

Compare PHIO & FLYX.WS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Phio Pharmaceuticals Corp.

PHIO

Phio Pharmaceuticals Corp.

HOLD

Current Price

$0.65

Market Cap

10.1M

Sector

Health Care

ML Signal

HOLD

FLYX.WS

flyExclusive Inc. Redeemable warrants each whole warrant exercisable for one Class A common stock at an exercise price of $11.50 per share

N/A

Current Price

$0.14

Market Cap

9.6M

ML Signal

N/A

Company Overview

Basic Information
Metric
PHIO
FLYX.WS
Founded
2003
N/A
Country
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Transportation Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
10.1M
9.6M
IPO Year
2011
N/A

Fundamental Metrics

Financial Performance
Metric
PHIO
FLYX.WS
Price
$0.65
$0.14
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 53.7K
N/A
Earning Date
11-05-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.70
N/A
52 Week High
$1.88
N/A

Technical Indicators

Market Signals
Indicator
PHIO
FLYX.WS
Relative Strength Index (RSI) 27.10 N/A
Support Level N/A N/A
Resistance Level $1.12 N/A
Average True Range (ATR) 0.07 0.00
MACD -0.01 0.00
Stochastic Oscillator 5.14 0.00

Price Performance

Historical Comparison
PHIO
FLYX.WS

About PHIO Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.

Share on Social Networks: